Tenet Health (THC)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$265.05+0.59%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Tenet Healthcare steadily grows revenue around 3% yearly. Profit rises with operating income reaching $1.3 billion. Free cash flow is strong near $2.3 billion. Moody's upgrade shows better credit and less debt.
Regulatory problems could slow growth and hurt profits. Management admits being behind on improving income. Growth is slow and risks remain from legal challenges.
The price is about 15% below our fair value near $244. Analysts expect about 3% revenue growth, which aligns with management's guidance. Our fair value is close to the Street median.
Breaks if: Free cash flow falls below $2.275B
Breaks if: Net income falls below $572M
Breaks if: Operating income fails to sustain near $1.3B
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on revenue growth and margin improvement. The current thesis state is intact, supported by strong recent earnings and a positive trajectory in key financial metrics.
The valuation is considered cheap compared to peers, with a notable expectations gap. The market seems to be pricing in some fragility due to weak execution quality, but not to an extreme extent.
Fundamentals are likely to continue improving, as management is on track with priorities like revenue growth and margin enhancement. Recent financial performance has been strong, although there is a low probability of missing future earnings expectations.
The thesis hinges on maintaining momentum in the healthcare sector and the performance of key competitors. Additionally, any reversal in guidance or a weakening jobs report could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Tenet Healthcare raised its full-year outlook after strong Q2 results. Analysts also increased their price targets for the stock. These changes suggest higher expectations for revenue and earnings. The overall sentiment in the healthcare sector may be stabilizing.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $21.15B in FY26
Focus on increasing revenue growth through strategic initiatives.
In the next 1 to 3 years, THC appears to be well-positioned, but it faces risks that could affect its credibility and market perception. Not investment advice.